# Best Peptides for Weight Loss Research: GLP-1 Agonists Compared (2026)
Weight loss is one of the most actively researched areas in peptide science. GLP-1 receptor agonists — compounds that mimic or enhance glucagon-like peptide-1 signaling — have transformed obesity research and clinical practice over the past decade. This guide compares the top research peptides studied for weight management, examining their mechanisms, efficacy data, and relative costs.
> Research Disclaimer: All compounds discussed here are research chemicals intended for laboratory and scientific investigation only. They are not approved for human consumption or therapeutic use unless prescribed by a licensed physician. This content is for educational purposes only.
---
Why GLP-1 Peptides Dominate Weight Loss Research
The discovery that GLP-1 receptor agonism could produce profound, sustained weight loss transformed metabolic research. GLP-1 is an incretin hormone secreted by intestinal L-cells in response to food. It:
- •Stimulates insulin secretion in a glucose-dependent manner
- •Suppresses glucagon release
- •Slows gastric emptying
- •Acts on hypothalamic receptors to reduce appetite
- •Promotes satiety signaling through vagal afferents
Unlike stimulant-based weight loss approaches, GLP-1 agonists work through physiological pathways without cardiovascular overstimulation. The result: research subjects lose significant body weight with favorable metabolic profiles.
---
Quick Comparison: Top Weight Loss Peptides at a Glance
| Peptide | Mechanism | Weekly Dose (research) | Avg. Weight Loss | Half-Life |
|---|---|---|---|---|
| Semaglutide | GLP-1 agonist | 0.5–2.4 mg SQ | 10–15% body weight | ~7 days |
| Tirzepatide | GLP-1 + GIP dual agonist | 5–15 mg SQ | 15–22% body weight | ~5 days |
| Retatrutide | GLP-1 + GIP + glucagon triple agonist | 4–12 mg SQ | 22–24% body weight | ~6 days |
| AOD-9604 | GH fragment, lipolysis activator | 250–500 mcg/day | Modest (3–5%) | ~30 min |
| 5-Amino-1MQ | NNMT inhibitor | Experimental | Moderate (animal data) | Unknown |
---
Semaglutide: The Gold Standard GLP-1 Agonist
Mechanism of Action
Semaglutide is a synthetic analog of native GLP-1 with 94% sequence homology. Modifications at position 8 (Aib substitution) and a C18 fatty acid chain attached via a linker at K34 confer resistance to DPP-IV cleavage and albumin binding, extending the half-life to approximately 7 days. This allows once-weekly subcutaneous injection.
Semaglutide activates GLP-1 receptors throughout the body:
- •Pancreatic beta cells: Enhances glucose-stimulated insulin secretion
- •Hypothalamus: Reduces food intake through POMC neuron activation and NPY/AgRP suppression
- •Brainstem: Signals satiety via area postrema and nucleus tractus solitarius
- •Periphery: Slows gastric emptying, reducing post-meal glucose excursions
Key Research Findings
The STEP trial program established semaglutide as a breakthrough weight loss intervention:
- •STEP 1 (2021): Adults with obesity receiving semaglutide 2.4 mg weekly lost an average of 14.9% of body weight vs. 2.4% with placebo over 68 weeks (Wilding et al., NEJM 2021)
- •STEP 4: Continued treatment maintained weight loss; discontinuation led to weight regain, demonstrating the need for sustained dosing
- •STEP 5: 2-year data confirmed sustained efficacy with BMI reductions averaging 16.0%
Cardiometabolic effects include significant reductions in waist circumference, systolic blood pressure (−6 mmHg), and HbA1c.
Research Considerations
- •Dose escalation is critical to minimize GI side effects (nausea, vomiting)
- •Storage: refrigerated (2–8°C); protect from light
- •Reconstitution: sterile bacteriostatic water
Typical Pricing Range
| Quantity | Avg. Research Price |
|---|---|
| 3 mg vial | –55 |
| 5 mg vial | –80 |
| 10 mg vial | –140 |
---
Tirzepatide: The GLP-1 + GIP Dual Agonist
Mechanism of Action
Tirzepatide is a first-in-class dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor co-agonist. The compound is built on a synthetic 39-amino-acid backbone with C20 fatty diacid attachment, providing ~5-day half-life.
The dual mechanism offers synergistic advantages:
- •GIP component: Enhances insulin secretion, promotes adipocyte lipid uptake in the fed state, and may have direct CNS effects on energy balance
- •GLP-1 component: Classic incretin + appetite suppression effects
- •Combined: Greater weight loss and glycemic control than either mechanism alone
Research suggests GIP receptor agonism at the level of adipose tissue may reduce the nausea/vomiting liability of pure GLP-1 agonism, making tirzepatide better tolerated at weight-effective doses.
Key Research Findings
The SURMOUNT program demonstrated superior weight loss vs. semaglutide:
- •SURMOUNT-1 (2022): 2,539 adults with obesity randomized to tirzepatide 5/10/15 mg or placebo. Mean weight reductions: −15.0%, −19.5%, −20.9% for the three doses vs. −3.1% placebo (Jastreboff et al., NEJM 2022)
- •SURMOUNT-4: 88-week data showed sustained 21% body weight loss with continued therapy
- •SURPASS-CVOT: Ongoing cardiovascular outcomes trial; interim data shows favorable effects on MACE
Notably, 50% of participants at the 15 mg dose achieved ≥20% weight loss — previously unachievable without surgical intervention.
Research Considerations
- •Available as lyophilized peptide for research reconstitution
- •Dose escalation protocol: start at 2.5 mg/week, increase by 2.5 mg monthly
- •May be stacked with insulin-sensitizing agents in metabolic research models
Typical Pricing Range
| Quantity | Avg. Research Price |
|---|---|
| 5 mg vial | –90 |
| 10 mg vial | –160 |
| 15 mg vial | –200 |
---
Retatrutide: The Triple Agonist (GLP-1 + GIP + Glucagon)
Mechanism of Action
Retatrutide represents the next frontier: a triagonist hitting GLP-1, GIP, and glucagon receptors simultaneously. Adding glucagon receptor agonism to the dual incretin approach offers a third weight-loss pathway:
- •Glucagon receptor: Increases hepatic glucose production (offset by insulin at therapeutic doses), drives thermogenesis via brown adipose tissue activation, stimulates lipolysis, and reduces liver fat
- •Combined triagonism: Creates overlapping metabolic pressures across energy intake, storage, and expenditure
The glucagon component is key to the exceptional weight loss magnitude — early data suggests metabolic rates may increase, not just caloric intake decrease.
Key Research Findings
Phase 2 data published in NEJM (Jastreboff et al., 2023) showed:
- •24.2% mean body weight loss at 48 weeks with 12 mg weekly
- •Dose-dependent responses from 4 mg (−8.7%) to 12 mg (−24.2%)
- •Significant reductions in liver fat, waist circumference, and cardiometabolic markers
- •Phase 3 trials (TRIUMPH program) currently underway
This 24% weight loss in 48 weeks is unprecedented for any non-surgical approach studied.
Research Considerations
- •Newer compound; less long-term safety data available
- •Elevated liver enzymes noted in some research subjects — hepatic monitoring recommended in protocols
- •Glucagon component may cause glycemic variability in insulin-dependent models
Typical Pricing Range
| Quantity | Avg. Research Price |
|---|---|
| 5 mg vial | –120 |
| 10 mg vial | –220 |
---
AOD-9604: The Growth Hormone Fragment
Mechanism of Action
AOD-9604 (Advanced Obesity Drug) is a synthetic analog of the C-terminal fragment of human growth hormone (hGH 176-191). Unlike full GH, it:
- •Does not bind GHR directly or stimulate IGF-1 production
- •Acts on beta-3 adrenergic receptors to stimulate lipolysis
- •Inhibits lipogenesis without the diabetogenic effects of full GH
- •Mimics the fat-metabolizing action of hGH without growth-promoting effects
The mechanism is fundamentally different from GLP-1 agonists — it doesn't affect appetite but directly targets fat oxidation.
Key Research Findings
- •Animal studies: Consistent reductions in body fat mass without affecting food intake or causing hyperglycemia
- •Phase 1 human trials: Favorable safety profile; no IGF-1 elevation; no insulin resistance
- •Phase 2b/3 (AOD9604-2001): Did not meet primary endpoints for weight loss in obese adults — effect size insufficient for pharmaceutical development
- •Current research use: Studied as an adjunct to GLP-1 agonists; potential role in reducing body fat without systemic hormonal effects
AOD-9604 is weaker than GLP-1 agonists for overall weight loss but occupies a niche: targeted lipolysis without appetite suppression, which may suit specific research models.
Typical Pricing Range
| Quantity | Avg. Research Price |
|---|---|
| 5 mg vial | –45 |
| 10 mg vial | –65 |
| 30 mg vial | –150 |
---
Peptide Comparison: Which to Choose for Your Research?
| Research Goal | Best Choice | Rationale |
|---|---|---|
| Maximum weight loss magnitude | Retatrutide | 24% body weight loss in 48 weeks |
| Proven efficacy + tolerability balance | Tirzepatide | 15–20% loss; dual mechanism; good tolerability |
| Established safety record + weekly dosing | Semaglutide | Most clinical data; widely studied |
| Targeted lipolysis without CNS effects | AOD-9604 | No appetite suppression; direct fat metabolism |
| Adipocyte-specific studies | AOD-9604 | beta-3 adrenergic pathway isolation |
| Insulin resistance models | Tirzepatide | Strong glycemic + weight effects |
| Liver fat reduction models | Retatrutide | Strongest hepatic fat reduction data |
---
Stacking Considerations
For research protocols examining additive or synergistic effects:
- •Semaglutide + AOD-9604: Appetite suppression + direct lipolysis; complementary mechanisms
- •GLP-1 agonist + MOTS-c: Metabolic + mitochondrial effects; emerging research area
- •GLP-1 agonist + GHK-Cu: Metabolic + tissue repair effects for comprehensive metabolic models
> Always consult peer-reviewed stacking protocols. Never combine research peptides without established safety profiles for the combination.
---
Sourcing: What to Look for in Vendors
When sourcing research peptides, prioritize suppliers who offer:
1. Third-party HPLC/MS analysis certificates verifying purity (>98%) and molecular weight
2. Endotoxin testing (LAL assay) for injectable preparations
3. Sterility testing or sterile-filtered production
4. Transparent supply chain: US-based synthesis or verified international labs
5. Reconstitution guides for lyophilized vials
Use Peptides.SO's Comparison Tool to compare current pricing and purity certifications across vetted vendors.
---
Key Research References
1. Wilding JPH et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002. PubMed
2. Jastreboff AM et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. PubMed
3. Jastreboff AM et al. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 389(6), 514–526. PubMed
4. Heffernan M et al. (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology, 142(12), 5182–5189.
---
Conclusion
The GLP-1 agonist class — from first-generation semaglutide through the dual and triple agonists — represents the most powerful pharmacological approach to weight management in research history. For researchers studying obesity mechanisms, insulin resistance, and metabolic disease, these compounds offer unmatched tools for understanding the biology of energy homeostasis.
The choice between semaglutide, tirzepatide, and retatrutide depends on your research objectives: established safety data favors semaglutide; maximum efficacy studies point toward retatrutide; balanced dual-mechanism research suits tirzepatide. AOD-9604 remains valuable for isolated lipolysis studies without systemic hormonal effects.
Use Peptides.SO's Stack Builder to model combination protocols, or the Calculator to determine dosing parameters for your research design.
For research purposes only. Not intended for human consumption. Always follow your institution's guidelines for research chemical handling.
---
2026 Vendor Comparison: Real Pricing From Our Database
The following pricing is sourced directly from our live database of 50+ verified vendors. All prices current as of early 2026.
Semaglutide Research Pricing (2026)
| Vendor | Price | Quantity | Price/mg | Notes |
|---|---|---|---|---|
| Polaris Peptides | $30.00 | 1 mg | $30/mg | Entry-level single vial |
| Royal Peptides | $45.00 | 1 mg | $45/mg | Testing docs available |
| HK Peptides Worldwide | $52.00 | 5 mg | $10.40/mg | Bulk value tier |
| Planet Peptide | $70.00 | 10 mg | $7/mg | Best value at 10mg |
| Strate Labs | $79.00 | 5 mg | $15.80/mg | US domestic |
| Manifest Peptides | $79.99 | 1 mg | $79.99/mg | Quality-focused |
| USA Peptide Store | $95.00 | 1 mg | $95/mg | US domestic |
| Real Peptides | $119.99 | 1 mg | $119.99/mg | Premium US vendor |
Market range: $30–$120 for 1mg; $7–$16/mg at 5–10mg quantities
Tirzepatide Research Pricing (2026)
| Vendor | Price | Quantity | Price/mg | Notes |
|---|---|---|---|---|
| Royal Peptides | $50.00 | 1 mg | $50/mg | Entry-level |
| Polaris Peptides | $55.00 | 1 mg | $55/mg | Verified US |
| HK Peptides Worldwide | $56.00 | 5 mg | $11.20/mg | Bulk savings |
| Planet Peptide | $70.00 | 10 mg | $7/mg | Best bulk price |
| Manifest Peptides | $89.99 | 1 mg | $89.99/mg | Quality + testing |
| Genesis Peptides | $99.00 | 1 mg | $99/mg | US domestic |
| NuRev Peptides | $119.99 | 10 mg | $12/mg | Mid-range bulk |
| Real Peptides | $129.99 | 1 mg | $129.99/mg | Premium vendor |
Market range: $50–$130 for 1mg; $7–$15/mg at 5–10mg quantities
Side-by-Side Cost Comparison
| Compound | 1mg Price | 10mg Price | Per-mg at 10mg | vs. Semaglutide |
|---|---|---|---|---|
| Semaglutide | $30–$80 | $50–$90 | $5–$9 | Baseline |
| Tirzepatide | $50–$90 | $70–$120 | $7–$12 | +15–30% premium |
| Retatrutide | $80–$150 | $120–$250 | $12–$25 | +60–100% premium |
| AOD-9604 | $15–$40 | $30–$70 | $3–$7 | 40–60% cheaper |
Bottom line: Tirzepatide costs 15–30% more than semaglutide at equivalent quantities. Retatrutide commands a substantial premium (~60–100% over semaglutide) reflecting its newer synthesis and limited supply. AOD-9604 is the most cost-effective option for lipolysis-focused research.
→ Compare live pricing across all vendors at Peptides.SO GLP-1 Comparison
---
Quick Decision Guide: Which Weight Loss Peptide Is Right for Your Research?
| Research Goal | Best Choice | Why |
|---|---|---|
| Maximum weight reduction effect | Tirzepatide (15mg) | ~20% body weight reduction in SURMOUNT-5 |
| Established safety/evidence base | Semaglutide | Most clinical data, longest track record |
| Triple-receptor GIP+GLP-1+GCG research | Retatrutide | Only available triple agonist |
| Isolated adipose lipolysis | AOD-9604 | Avoids systemic incretin effects |
| Budget-constrained / larger cohorts | AOD-9604 or Semaglutide | Lowest cost per experiment |
| Cardiovascular model with high-risk subjects | Semaglutide | STEER study advantage in established CVD |
For stacking considerations and multi-compound protocol design, see our Peptide Stack Builder and Dosing Calculator.
> For research purposes only. All compounds are research-grade peptides not approved for human use. Pricing data current as of early 2026 and subject to change.
---
Further Reading:
- •Semaglutide vs Tirzepatide: Price, Efficacy, and Supplier Comparison 2026
- •GLP-1 Receptor Agonists: Complete Research Overview (Semaglutide, Tirzepatide, Liraglutide & More)
- •Best Peptides for Anti-Aging Research: Science-Backed Compounds (2026)
- •Best Peptides for Muscle Growth Research: Growth Hormone Secretagogues (2026)
- •Reconstitution Calculator
- •Peptide Stack Builder